The Board of Directors of Fresenius Kabi Pharmaceuticals Holding Inc. (APCVZ), the parent company of APP Pharma Inc., announced that Thomas Silberg, president and chief executive officer of APP, will retire effective December 31, 2009.
John Ducker, a member of the management board of Fresenius Kabi AG responsible for the Fresenius Kabi Innovation Centre, was named by the board as president and chief executive officer.
Under a succession plan, Tom will serve as a consultant for one year to ensure a smooth transition as Ducker assumes his new responsibilities.
For comments and feedback: editorial@rttnews.com